| Not Yet Recruiting | Navigation Intervention for Adolescent and Young Adult Cancer Survivors NCT07406087 | Kaiser Permanente | N/A |
| Not Yet Recruiting | An International Field Study of the Reliability and Validity of a Disease-Specific Questionnaire Module (the Q NCT07465133 | Helios University Hospital Wuppertal | — |
| Not Yet Recruiting | Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression NCT07168083 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Not Yet Recruiting | A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. NCT07389239 | University of Chicago | Phase 1 / Phase 2 |
| Not Yet Recruiting | Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal NCT07532148 | Chong Kun Dang Pharmaceutical | Phase 1 |
| Recruiting | Study Evaluating Safety, Tolerability, and Metabolism of Niraparib NCT06412120 | University of Miami | Phase 4 |
| Not Yet Recruiting | CYTALUX Dose Extension Study NCT07469202 | On Target Laboratories, LLC | Phase 4 |
| Not Yet Recruiting | PITCH - Impacting Hereditary Cancer Testing NCT07090109 | Rachel Miller | N/A |
| Not Yet Recruiting | Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Fron NCT06139783 | Oncare Madrid | N/A |
| Recruiting | Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer NCT06930755 | Nerviano Medical Sciences | Phase 1 |
| Recruiting | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maint NCT07225270 | Genmab | Phase 3 |
| Recruiting | Cognitive Impact of Neoadjuvant Chemotherapy for Ovarian Cancer NCT07125209 | University of Wisconsin, Madison | — |
| Not Yet Recruiting | Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors NCT07524322 | Regor Pharmaceuticals Inc. | Phase 1 |
| Recruiting | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors NCT07517198 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 |
| Not Yet Recruiting | NeoAdjuvant ChemoTherapy With KELIM Guided Interval vs. Delayed Interval Debulking Surgery NCT07382479 | Aristotle University Of Thessaloniki | N/A |
| Not Yet Recruiting | QLS5132 Combination Therapy in Advanced Solid Tumors NCT07453394 | Qilu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent NCT07489300 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Not Yet Recruiting | An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Pr NCT07420010 | Weijia Fang, MD | EARLY_Phase 1 |
| Recruiting | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors NCT07424547 | Conjupro Biotherapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT NCT04520139 | University of California, Irvine | Phase 1 / Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. NCT07303387 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Not Yet Recruiting | Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer NCT07382713 | Jinhua Zhou | Phase 2 |
| Recruiting | Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients NCT07211659 | Theolytics Limited | Phase 1 |
| Not Yet Recruiting | To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relap NCT07370818 | Onconic Therapeutics Inc. | Phase 2 |
| Recruiting | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871 | Radiopharm Theranostics, Ltd | Phase 1 / Phase 2 |
| Recruiting | Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer NCT07371104 | Daewoong Pharmaceutical Co. LTD. | Phase 1 |
| Recruiting | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cance NCT06366490 | PhotonPharma, Inc. | Phase 1 |
| Not Yet Recruiting | An Exploratory Study of Detection of Endometrial and Ovarian Cancers in Vaginal Samples Retrieved by the Ellel NCT07429799 | Ellele Health | N/A |
| Recruiting | Cancer Loyalty Card Study 2 (CLOCS-2) NCT06447064 | Imperial College London | — |
| Recruiting | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676 | Essen Biotech | Phase 1 / Phase 2 |
| Not Yet Recruiting | Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic T NCT07387263 | Unity Health Toronto | N/A |
| Recruiting | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors NCT07410494 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detect NCT07491081 | Queensland Centre for Gynaecological Cancer | N/A |
| Not Yet Recruiting | SL-28 for Advanced Solid Tumours NCT07341737 | Second Life Therapeutics | Phase 1 / Phase 2 |
| Not Yet Recruiting | The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Che NCT07401654 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or NCT07402915 | AstraZeneca | Phase 1 |
| Recruiting | A Study of Isoquercetin in People With Ovarian Cancer NCT07303894 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients NCT07361471 | Centre Jean Perrin | N/A |
| Recruiting | Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer NCT06815497 | Tyler J Curiel | Phase 2 |
| Not Yet Recruiting | The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients NCT07385976 | Far Eastern Memorial Hospital | — |
| Not Yet Recruiting | Surgeons' Ability to Predict Pathological and Molecular Features of Peritoneal Carcinomatosis in Ovarian Cance NCT07321730 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Not Yet Recruiting | Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovaria NCT07239622 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Not Yet Recruiting | Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receivi NCT07362147 | Taipei Veterans General Hospital, Taiwan | N/A |
| Not Yet Recruiting | A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neo NCT07355010 | Qinglei Gao | Phase 2 |
| Not Yet Recruiting | Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy NCT07340164 | Yonsei University | Phase 2 |
| Recruiting | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial NCT07447050 | University of California, Irvine | Phase 2 |
| Recruiting | The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and NCT06717295 | Javier Toledo | — |
| Recruiting | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants W NCT07444814 | Whitehawk Therapeutics, Inc. | Phase 1 |
| Recruiting | Autophagy Maintenance (AUTOMAIN) NCT06971744 | Medical University of South Carolina | Phase 2 |
| Recruiting | Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resist NCT07214779 | Incyte Corporation | Phase 3 |
| Recruiting | A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Ca NCT07042802 | Nanjing Leads Biolabs Co.,Ltd | Phase 1 / Phase 2 |
| Recruiting | Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer NCT07261683 | Obstetrics & Gynecology Hospital of Fudan University | Phase 2 |
| Recruiting | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through th NCT07278336 | AbbVie | Phase 1 |
| Not Yet Recruiting | Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance NCT07269574 | Tongji Hospital | — |
| Recruiting | Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior NCT07098182 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Recruiting | A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intrav NCT07059845 | AbbVie | Phase 2 |
| Recruiting | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression NCT07023627 | Incyte Corporation | Phase 2 |
| Not Yet Recruiting | Prediction of Ovarian Cancer Histotypes and Surgical Outcome NCT07057167 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours NCT06926075 | Filamon LTD | Phase 1 / Phase 2 |
| Recruiting | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors NCT07216105 | Fate Therapeutics | Phase 1 |
| Recruiting | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors NCT07182149 | Normunity AccelCo, Inc. | Phase 1 |
| Not Yet Recruiting | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer NCT07146919 | Centre Leon Berard | Phase 1 / Phase 2 |
| Recruiting | A Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Her NCT07532434 | Peking University Third Hospital | — |
| Recruiting | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations NCT07109726 | Terremoto Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer NCT06964009 | Elizabeth Stover, MD, PhD | Phase 1 |
| Recruiting | Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian NCT07167433 | AstraZeneca | — |
| Recruiting | DESTINY-PANTUMOUR04 NCT07124000 | AstraZeneca | — |
| Not Yet Recruiting | Clinical Validation of Sophia Genetics Assay NCT07160010 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors NCT07181720 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer NCT07171528 | National Cancer Center, Korea | Phase 2 |
| Recruiting | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection NCT06503146 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT NCT06412510 | Case Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tu NCT07044349 | Beijing Biostar Pharmaceuticals Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Proactive Hemodynamic Management During Cytoreductive Surgery and HIPEC NCT07070973 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Not Yet Recruiting | Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncolog NCT06871787 | Istanbul University | Phase 4 |
| Not Yet Recruiting | OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Tre NCT07153705 | Beihua Kong | — |
| Enrolling By Invitation | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Product NCT06885424 | A2 Biotherapeutics Inc. | — |
| Recruiting | Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology) NCT07120945 | Medtronic - MITG | N/A |
| Recruiting | Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors NCT07156253 | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Phase 1 |
| Recruiting | IDOV-Immune for Advanced Solid Tumors NCT06910657 | ViroMissile, Inc. | Phase 1 |
| Not Yet Recruiting | Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors NCT07088588 | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Phase 1 |
| Active Not Recruiting | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations NCT07038369 | Atavistik Bio, Inc | Phase 1 |
| Recruiting | The Better, Harder, Faster, Stronger Study NCT07220512 | Wake Forest University Health Sciences | — |
| Recruiting | A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer NCT06888921 | Compugen Ltd | Phase 1 / Phase 2 |
| Recruiting | Sample Collection for Ongoing Research and Product Evaluation Study NCT07318051 | Natera, Inc. | — |
| Recruiting | Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer NCT07100288 | Complejo Hospitalario Universitario Insular Materno Infantil | — |
| Terminated | Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada NCT07035067 | PeriPharm | — |
| Enrolling By Invitation | Clinician Nudge to Referral of Adnexal Masses to Gynecologic Oncology NCT07078409 | Abramson Cancer Center at Penn Medicine | N/A |
| Recruiting | UNTOLD Ovarian Cancer Unmet Needs Survey NCT07070726 | Masonic Cancer Center, University of Minnesota | — |
| Recruiting | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adju NCT06915025 | Imunon | Phase 3 |
| Terminated | A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum NCT07000344 | Peking Union Medical College Hospital | N/A |
| Enrolling By Invitation | Prehabilitation in Ovarian Cancer Patients During Chemiotherapy Before Cytoreductive Surgery. NCT07058753 | Medical University of Silesia | N/A |
| Recruiting | PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombinati NCT07472140 | N.N. Alexandrov National Cancer Centre | Phase 2 / Phase 3 |
| Recruiting | Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib NCT07033819 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Not Yet Recruiting | Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer NCT06977594 | Seoul National University Hospital | N/A |
| Recruiting | Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ova NCT07125391 | Bai-Rong Xia | Phase 2 |
| Recruiting | A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleter NCT07069335 | Boryung Pharmaceutical Co., Ltd | Phase 1 |
| Not Yet Recruiting | Ultrasound Training Program for Gynecologic Cancer Staging in Residents NCT07028229 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer NCT07030907 | Outpace Bio, Inc. | Phase 1 |
| Not Yet Recruiting | Minimally Invasive Interval Debulking Surgery in Advanced Ovarian Cancer NCT07031908 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Completed | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors NCT06973161 | AstraZeneca | — |
| Not Yet Recruiting | Proteomic Analysis of Patients Undergoing Bariatric Surgery NCT06787807 | Universidade Federal de Pernambuco | N/A |
| Recruiting | Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer NCT06545604 | M.D. Anderson Cancer Center | N/A |
| Recruiting | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187 | Dren Bio | Phase 1 |
| Not Yet Recruiting | SCT-001 CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer NCT06846424 | Shanghai Gynecologic Oncology Group | Phase 1 |
| Not Yet Recruiting | Exosome-based Recurrence Score for Post-Treatment Ovarian Cancer NCT06925126 | Fudan University | — |
| Withdrawn | Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovar NCT04542603 | University of Alabama at Birmingham | Phase 1 |
| Not Yet Recruiting | SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer NCT06990503 | Tongji Hospital | Phase 3 |
| Not Yet Recruiting | SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer NCT06990516 | Tongji Hospital | Phase 1 / Phase 2 |
| Recruiting | Evaluation of Polygenic Risk Score for Epithelial OVarian cancEr Risk Prediction: the PROVE Study NCT06935344 | Catholic University of the Sacred Heart | — |
| Recruiting | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer NCT06787612 | Regeneron Pharmaceuticals | Phase 2 |
| Recruiting | Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Adva NCT06954584 | Tongji Hospital | Phase 3 |
| Recruiting | Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer NCT07023484 | The University of Hong Kong | Phase 2 |
| Recruiting | SLV-154 Treatment of Metastatic Solid Tumors NCT06771219 | Solve Therapeutics | Phase 1 |
| Recruiting | EXoPERT EMERALD Clinical Study NCT07186296 | EXoPERT | — |
| Recruiting | Genetically Modified T Cells Against Ovarian Cancer NCT03184753 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Recruiting | The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During I NCT07460180 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies NCT07064018 | University of California, Irvine | Phase 1 / Phase 2 |
| Recruiting | Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer NCT07067255 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Lead-212 PSV359 Therapy for Patients With Solid Tumors NCT06710756 | Perspective Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Healthy Volunteers Study NCT06962059 | Abramson Cancer Center at Penn Medicine | — |
| Recruiting | A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521 | Tanabe Pharma America, Inc. | Phase 1 / Phase 2 |
| Recruiting | The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer NCT06665945 | University of Utah | — |
| Recruiting | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers NCT06906341 | Corcept Therapeutics | Phase 2 |
| Active Not Recruiting | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors NCT06714617 | SystImmune Inc. | Phase 1 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus NCT06824467 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer NCT06890858 | Zhejiang Provincial People's Hospital | Phase 2 |
| Recruiting | A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors NCT07029399 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tu NCT06799065 | Accent Therapeutics | Phase 1 |
| Recruiting | Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in NCT06819007 | Daiichi Sankyo | Phase 3 |
| Recruiting | A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer NCT06840002 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors NCT06710548 | Dana-Farber Cancer Institute | N/A |
| Active Not Recruiting | METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer NCT06884345 | Anhui Provincial Cancer Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study of SHR-A1811 in Subjects With Ovarian Cancer NCT06828354 | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Recruiting | HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06855069 | Hansoh BioMedical R&D Company | Phase 3 |
| Recruiting | Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progre NCT06839144 | Tel-Aviv Sourasky Medical Center | Phase 2 |
| Recruiting | A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic C NCT06738966 | Shanghai Best-Link Bioscience, LLC | Phase 1 |
| Not Yet Recruiting | Lipid Mediators & Cancer: Montelukast, SPM, and Almonds NCT06887673 | University of South Florida | EARLY_Phase 1 |
| Recruiting | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation NCT06778863 | Clasp Therapeutics, Inc. | Phase 1 |
| Recruiting | A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advan NCT06769152 | Shanghai Henlius Biotech | Phase 2 |
| Recruiting | Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro NCT05952453 | University of Alabama at Birmingham | Phase 2 |
| Recruiting | Ovarian Cancer Radiomics Approach in CT Led Evaluation NCT06817174 | Imperial College Healthcare NHS Trust | — |
| Completed | GYNecologic Cancer-Related COGnitive Impairment NCT06662435 | Northwestern University | N/A |
| Recruiting | Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screenin NCT06760507 | Emory University | N/A |
| Completed | A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry NCT06925113 | Daiichi Sankyo | — |
| Recruiting | Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovar NCT06543537 | Dana-Farber Cancer Institute | N/A |
| Not Yet Recruiting | JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer NCT06751485 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 3 |
| Recruiting | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors NCT06695845 | Jazz Pharmaceuticals | Phase 2 |
| Recruiting | Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovari NCT06588322 | Institut Claudius Regaud | N/A |
| Recruiting | A Phase 1 Study of LNCB74 in Advanced Solid Tumors NCT06774963 | NextCure, Inc. | Phase 1 |
| Recruiting | Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Lin NCT07285941 | Zhejiang Cancer Hospital | Phase 2 |
| Not Yet Recruiting | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors NCT06652529 | Aromics Therapeutics | Phase 1 |
| Not Yet Recruiting | Reproductive Health Outcomes in Young Patients With Ovarian Cancer After Surgical Treatment: A Retrospective S NCT06777147 | Assiut University | — |
| Recruiting | OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study NCT06611072 | Gynaecologisch Oncologisch Centrum Zuid | N/A |
| Recruiting | Ultrasound-guided Tru-cut Biopsy in Patients with Suspected Ovarian Cancer: Adequacy, Accuracy, Safety and Pat NCT06689605 | University Hospital Hradec Kralove | — |
| Withdrawn | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors NCT06681870 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Recruiting | Trop2-targeted immunoPET Imaging of Solid Tumors NCT06851663 | RenJi Hospital | Phase 2 / Phase 3 |
| Recruiting | Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin NCT06677190 | Dana-Farber Cancer Institute | Phase 2 |
| Recruiting | Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology NCT06392997 | ZIWIG | — |
| Recruiting | Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression NCT06180356 | MedSIR | Phase 2 |
| Recruiting | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial NCT06580002 | University of California, Irvine | Phase 2 |
| Not Yet Recruiting | Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors NCT06730581 | Beijing Biostar Pharmaceuticals Co., Ltd. | Phase 2 |
| Not Yet Recruiting | Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer NCT06188455 | The First Affiliated Hospital of Xiamen University | Phase 3 |
| Not Yet Recruiting | The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer NCT06283875 | Geneplus-Beijing Co. Ltd. | — |
| Not Yet Recruiting | The Role of CircDENND4C in Epithelial Ovarian Cancer NCT06617585 | Assiut University | — |
| Recruiting | Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer NCT06735326 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence NCT06430541 | University of Colorado, Denver | Phase 1 |
| Recruiting | Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors NCT06666270 | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | Phase 1 |
| Recruiting | Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors NCT06646627 | Stanford University | Phase 1 |
| Terminated | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Col NCT06760702 | Aurigene Discovery Technologies Limited | Phase 2 |
| Not Yet Recruiting | High Definition Profiling of Ovarian Cancer Ascites NCT06553742 | European Institute of Oncology | — |
| Active Not Recruiting | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients NCT06682572 | Verastem, Inc. | Phase 2 |
| Active Not Recruiting | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC NCT06433219 | EMD Serono Research & Development Institute, Inc. | Phase 2 |
| Recruiting | Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Ca NCT06040970 | Icahn School of Medicine at Mount Sinai | Phase 1 / Phase 2 |
| Recruiting | A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Plati NCT05460000 | North Eastern German Society of Gynaecological Oncology | Phase 2 |
| Active Not Recruiting | A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY NCT06497270 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer NCT06321484 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer NCT06624878 | Zhejiang Cancer Hospital | N/A |
| Recruiting | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors NCT06617169 | Monopar Therapeutics | Phase 1 |
| Completed | Enhanced Assistance During Radiotherapy for Unmet Essential Needs NCT06582849 | Washington University School of Medicine | N/A |
| Recruiting | Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors NCT06843629 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Recruiting | Prospective Evaluation of the Role of MRI in Ovarian Masses During Pregnancy NCT06635837 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Not Yet Recruiting | Exosome-based OCS Scores for Predicting Ovarian Cancer Recurrence NCT06558019 | Lei Li | — |
| Recruiting | A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL) NCT06594679 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 1 / Phase 2 |
| Recruiting | Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years NCT06572735 | Hospices Civils de Lyon | — |
| Recruiting | Trial of THEO-260 in Ovarian Cancer Patients NCT06618235 | Theolytics Limited | Phase 1 / Phase 2 |
| Recruiting | MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Mass NCT06638593 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and NCT06836219 | Consorzio Oncotech | — |
| Recruiting | A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumor NCT06873555 | Heronova Pharmaceuticals | Phase 1 / Phase 2 |
| Terminated | A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers NCT06376253 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First P NCT06614790 | Pomeranian Medical University Szczecin | — |
| Not Yet Recruiting | A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence Du NCT06541171 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Not Yet Recruiting | Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer NCT06552858 | Fudan University | Phase 2 |
| Not Yet Recruiting | Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer NCT06574763 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients NCT06544460 | Fudan University | Phase 2 |
| Recruiting | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017 | Nammi Therapeutics Inc | Phase 1 |
| Active Not Recruiting | Diet, Hepcidin, and Chemotherapy RDI NCT06483997 | George Washington University | — |
| Recruiting | Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy NCT06268665 | University of California, Davis | Phase 2 |
| Active Not Recruiting | Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors NCT06545942 | MOMA Therapeutics | Phase 1 |
| Recruiting | Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patient NCT06476184 | ARCAGY/ GINECO GROUP | Phase 3 |
| Not Yet Recruiting | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors NCT06531486 | NovaOnco Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells NCT06305299 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Recruiting | INSPIRE: a Multi-Cancer Early Detection Study NCT06440018 | Singlera Genomics Inc. | — |
| Recruiting | Ultrasound RF Data for Discriminating Between Benign and Malignant Ovarian Masses NCT06473766 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Active Not Recruiting | Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer NCT06342986 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Recruiting | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069 | Eli Lilly and Company | Phase 1 |
| Terminated | A Study of PHN-010 in Patients With Advanced Solid Tumors NCT06457997 | Pheon Therapeutics | Phase 1 |
| Active Not Recruiting | Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer NCT06436248 | Abramson Cancer Center at Penn Medicine | — |
| Recruiting | An Exploratory Clinical Study of Statins for Improving Chemotherapy and Maintenance in Patients With Ovarian C NCT06468254 | Anhui Provincial Cancer Hospital | Phase 2 |
| Recruiting | Fluzoparib Neoadjuvant Therapy for Ovarian Cancer NCT06541314 | Qilu Hospital of Shandong University | Phase 2 |
| Recruiting | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors NCT06399757 | Apollo Therapeutics Ltd | Phase 1 / Phase 2 |
| Recruiting | A Cohort Establishment Study of Total Management of Ovarian Cancer NCT06018935 | Sichuan Cancer Hospital and Research Institute | — |
| Recruiting | A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Ar NCT06504147 | Oncoinvent Solutions AS | Phase 2 |
| Recruiting | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenoc NCT06303505 | Tubulis GmbH | Phase 1 / Phase 2 |
| Recruiting | Feasibility of CALM in Patients With Ovarian Cancer NCT06459271 | University Health Network, Toronto | N/A |
| Recruiting | Satisfactory Debulking Prediction Model for Advanced Ovarian Cancer Based on PET-CT Image Data NCT06533709 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Completed | Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients NCT06007586 | Sichuan Cancer Hospital and Research Institute | Phase 3 |
| Recruiting | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors NCT06337084 | Monopar Therapeutics | Phase 1 |
| Recruiting | Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) NCT05804370 | NX Development Corp | Phase 3 |
| Recruiting | Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test NCT06445621 | Uppsala University Hospital | — |
| Recruiting | Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer NCT07022535 | The University of Hong Kong | Phase 2 |
| Recruiting | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Main NCT06437353 | Anhui Provincial Cancer Hospital | Phase 2 |
| Not Yet Recruiting | Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer NCT05921149 | Endeavor Health | N/A |
| Active Not Recruiting | A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other NCT06390995 | Takeda | Phase 1 / Phase 2 |
| Active Not Recruiting | Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertensio NCT06515678 | Groupe Hospitalier Pitie-Salpetriere | — |
| Active Not Recruiting | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction NCT06253520 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies NCT06395519 | 858 Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Ca NCT05145569 | Haider Mahdi | Phase 2 |
| Recruiting | SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06394492 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 |
| Active Not Recruiting | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) NCT05973487 | TScan Therapeutics, Inc. | Phase 1 |
| Recruiting | Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epitheli NCT06395844 | Anhui Provincial Cancer Hospital | Phase 1 / Phase 2 |
| Recruiting | Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovar NCT06907771 | University Hospital, Strasbourg, France | — |
| Not Yet Recruiting | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors NCT06383507 | Zhejiang University | Phase 1 |
| Recruiting | The Gynecological Cancer Associated Thrombosis (GynCAT) Study NCT06284343 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen NCT06251947 | Shandong University | Phase 2 |
| Completed | Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 NCT06386653 | Tomsk National Research Medical Center of the Russian Academy of Sciences | Phase 1 |
| Not Yet Recruiting | SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours NCT06329323 | Imperial College London | — |
| Suspended | Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging NCT05866679 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors NCT06276491 | Xencor, Inc. | Phase 1 |
| Recruiting | ASk Questions in GYnecologic Oncology (ASQ-GYO) NCT06339827 | Ira Winer | N/A |
| Recruiting | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With So NCT06051695 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Appraising Medical Trial Experiences of Ovarian Cancer Patients NCT05801796 | Power Life Sciences Inc. | — |
| Unknown | BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary NCT06304922 | Assiut University | — |
| Unknown | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis NCT06363123 | Beijing Friendship Hospital | — |
| Recruiting | Evaluating Efficacy and Tolerability of Anticancer Drug Therapies for the Treatment of Gynecologic and Breast NCT06800612 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors NCT06380660 | Acerand Therapeutics (Shanghai) Limited | Phase 1 / Phase 2 |
| Recruiting | Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy NCT06024109 | Aesculap AG | — |
| Recruiting | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors NCT06257264 | BeiGene | Phase 1 |
| Recruiting | Frailty, Quality Of Life and Early Reversal of Temporary Defunctioning Stoma in Ovarian Cancer NCT06298877 | Sahar Salehi | N/A |
| Recruiting | Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer NCT06216496 | University Hospital, Grenoble | N/A |
| Withdrawn | Non-Viral TCR Gene Therapy NCT04102436 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 | MacroGenics | Phase 1 |
| Active Not Recruiting | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors NCT06238479 | Eli Lilly and Company | Phase 1 |
| Completed | MicroFluO: FLUorescence-guided Surgery for Ovarian Cancer NCT05633836 | Assistance Publique - Hôpitaux de Paris | N/A |
| Active Not Recruiting | A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer NCT06483425 | Tongji Hospital | — |
| Recruiting | Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surg NCT06290193 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | HRD Tests for Ovarian cancER NCT06152731 | Centre Francois Baclesse | Phase 2 |
| Not Yet Recruiting | A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer NCT06211023 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 / Phase 3 |
| Recruiting | A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumor NCT06234423 | OnCusp Therapeutics, Inc. | Phase 1 |
| Recruiting | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors NCT06293898 | SystImmune Inc. | Phase 1 |
| Recruiting | Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) NCT06377267 | Vall d'Hebron Institute of Oncology | Phase 2 |
| Recruiting | Spatial Radiogenomics of Ovarian Cancer NCT06324175 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Completed | Improved Early Diagnosis in Female Pelvic Cancer With OC Detect NCT06613230 | Region Skane | — |
| Recruiting | A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Canc NCT07469709 | Fondazione del Piemonte per l'Oncologia | — |
| Active Not Recruiting | A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course o NCT06240598 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China NCT06238284 | Chongqing University Cancer Hospital | — |
| Recruiting | Transforming Ovarian Cancer Diagnostic Pathways NCT06129968 | Professor Sudha Sundar | — |
| Withdrawn | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors NCT06161493 | Haider Mahdi | Phase 1 |
| Active Not Recruiting | Nudge to Gynecologic Oncology NCT06451263 | Abramson Cancer Center at Penn Medicine | N/A |
| Withdrawn | Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination De NCT06120972 | Alexander B Olawaiye, MD | Phase 2 |
| Withdrawn | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast C NCT05905341 | Pfizer | Phase 1 |
| Recruiting | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologi NCT06215950 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Unknown | Exercise and Nutrition Intervention in Ovarian Cancer NCT06250686 | Universitätsklinikum Hamburg-Eppendorf | N/A |
| Terminated | PRO1107 in Patients With Advanced Solid Tumors NCT06171789 | Genmab | Phase 1 / Phase 2 |
| Completed | ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer NCT07439328 | Institute of Oncology Ljubljana | N/A |
| Not Yet Recruiting | The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian Cancer NCT05931055 | Peking Union Medical College Hospital | — |
| Recruiting | SEQUENTIAL PROFILING OF TUMOR-DERIVED CIRCULATING CELL-FREE DNA (ctDNA) IN ADVANCED OVARIAN CANCER PATIENTS NCT06071286 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC ) NCT06249308 | Fudan University | — |
| Recruiting | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer NCT06014190 | Hansoh BioMedical R&D Company | Phase 2 |
| Completed | Doxil/Caelyx BE Study NCT05567601 | Baxter Healthcare Corporation | Phase 1 |
| Recruiting | The Registry of Genetic Alterations of Taiwan Ovarian Cancer NCT06127446 | National Health Research Institutes, Taiwan | — |
| Recruiting | Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients NCT06083844 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovari NCT06660147 | ARCAGY/ GINECO GROUP | — |
| Unknown | Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARP NCT06161272 | Guangxi Medical University | Phase 2 |
| Terminated | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors NCT06065059 | Tango Therapeutics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vacci NCT05964361 | University Hospital, Antwerp | Phase 1 / Phase 2 |
| Recruiting | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments NCT06799637 | Evopoint Biosciences Inc. | Phase 1 / Phase 2 |
| Recruiting | Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inh NCT05704621 | Korea University Guro Hospital | Phase 2 |
| Recruiting | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumo NCT06010875 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Unknown | Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration NCT06281860 | Dr Jean Yannis PERENTES | Phase 1 |
| Recruiting | ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Patie NCT06844136 | Pierian Biosciences | — |
| Recruiting | [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer NCT05903807 | Aalborg University Hospital | Phase 2 |
| Recruiting | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cance NCT05983276 | Loyola University | Phase 2 |
| Recruiting | Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA). NCT06229522 | Centro di Riferimento Oncologico - Aviano | — |
| Active Not Recruiting | Assessing the Time Demands of Cancer NCT05708703 | Masonic Cancer Center, University of Minnesota | — |
| Completed | Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Vo NCT06063343 | Novakand Pharma AB | Phase 1 |
| Recruiting | Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors NCT05799274 | Radiopharm Theranostics, Ltd | Phase 1 |